Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB6411 in advanced malignant tumors
NCT07043751Phase 1Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB6411 in cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 24 months, Maximum Tolerated Dose at 24 months and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
TQB6411
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07043751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043751.